Abstract
We report three patients with rheumatoid arthritis (RA) who were treated with anti-TNF-α agents and who developed drug-induced lupus (DIL). Two of them received etanercept and the remainder adalimumab. We also present the favorable response observed with the withdrawal of the anti-TNF-alpha agents and the introduction of rituximab. Through this intervention, we observed a very good control of the activity of both DIL and RA without additional adverse reactions.
MeSH terms
-
Adalimumab
-
Adult
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
-
Antirheumatic Agents / adverse effects*
-
Arthritis, Rheumatoid / diagnosis
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / immunology
-
Drug Substitution
-
Etanercept
-
Female
-
Humans
-
Immunoglobulin G / adverse effects*
-
Lupus Erythematosus, Systemic / chemically induced
-
Lupus Erythematosus, Systemic / diagnosis
-
Lupus Erythematosus, Systemic / drug therapy*
-
Middle Aged
-
Receptors, Tumor Necrosis Factor
-
Rituximab
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antirheumatic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Rituximab
-
Adalimumab
-
Etanercept